AB122 Platform Study

AB122 will be administered with 360 mg/body given by infusion over 60 minutes Q3W.

AB122 will be administered with 240 mg/body given by infusion over 60 minutes Q2W.

TAS-116 will be administered orally in 5-day on and 2-day off schedule on an empty stomach at least 1 hour before or 2 hour after eating.

AB122 will be administered with 240 mg/body given by infusion over 60 minutes Q2W.

TAS-116 will be administered orally in 5-day on and 2-day off schedule on an empty stomach at least 1 hour before or 2 hour after eating.

AB122 will be administered with 240 mg/body given by infusion over 60 minutes Q2W.

TAS-116 will be administered orally in 5-day on and 2-day off schedule on an empty stomach at least 1 hour before or 2 hour after eating.

AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.

TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.

AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.

TAS-115 will be administered orally in 5-day on and 2-day off schedule on an empty stomach at least 1 hour before or 2 hours after eating.

AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.

TAS-115 will be administered orally in 5-day on and 2-day off schedule on an empty stomach at least 1 hour before or 2 hours after eating.

AB122 will be administered with 240 mg/body given by infusion over 60 minutes every 2 weeks.

TAS-102 will be administered orally twice daily at a dose calculated based on body surface area (BSA) within 1 hour after morning and evening meals for 5 days, a week with 2 days rest for 2 weeks, followed by a 14-day rest, repeated every 4 weeks.

Ramucirumab will be administered by infusion at a dose calculated using the body weight over approximately 60 minutes every 2 weeks.

AB122 will be administered with 240 mg/body given by infusion over 60 minutes every 2 weeks.

TAS-102 will be administered orally twice daily at a dose calculated based on BSA within 1 hour after morning and evening meals for 5 days, a week with 2 days rest for 2 weeks, followed by a 14-day rest, repeated every 4 weeks.

Bevacizumab will be administered by infusion at a dose calculated using the body weight over approximately 90 minutes every 2 weeks.

AB122 will be administered with 240 mg/body given by infusion over 60 minutes Q2W.

AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.

TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.

Fluorouracil will be administered with 800 mg/m2/day given by continuous intravenous infusion from Day 1 to Day 5.

Cisplatin will be administered with 80 mg/m2 given by infusion every 3 weeks.

AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.

TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.

AB154 will be administered with 1200 mg/body given by infusion over 60 minutes every 3 weeks.

AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.

TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.

Fluorouracil will be administered with 1000 mg/m2/day given by continuous intravenous infusion from Day 1 to Day 4.

Carboplatin will be administered with AUC 5 given by infusion every 3 weeks.

Cisplatin will be administered with 100 mg/m2 given by infusion every 3 weeks.

AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.

TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.

AB154 will be administered with 1200 mg/body given by infusion over 60 minutes every 3 weeks.

AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.

TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.

Carboplatin will be administered with AUC 6 given by infusion every 3 weeks.

Nab-Paclitaxel will be administered with 100 mg/m2 given by infusion on Day 1, Day 8 and Day 15.

AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.

TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.

Cisplatin will be administered with 25 mg/m2 given by infusion on Day 1 and Day 8.

Gemcitabine will be administered with 1000 mg/m2 given by infusion on Day 1 and Day 8.

AB122 will be administered with 240 mg/body given by infusion over 60 minutes every 2 weeks.

TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.

Nab-Paclitaxel will be administered with 125 mg/m2 given by infusion on Day 1, Day 8 and Day 15.

Gemcitabine will be administered with 1000 mg/m2 given by infusion on Day 1, Day 8 and Day 15.